Core Viewpoint - The company anticipates a significant reduction in net loss for the first half of the year, projecting a loss not exceeding RMB 10 million, which represents a decrease of at least 83% compared to the same period last year [1] Group 1: Financial Performance - The expected net loss for the reporting period is projected to be less than RMB 10 million, marking a reduction of no less than 83% [1] - The reduction in net loss is primarily attributed to the sales of the VitaFlow Liberty® transcatheter aortic valve and its delivery system, which have been sold in over 20 countries/regions overseas, resulting in more than a twofold increase in overseas revenue compared to the same period last year [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its delivery system are making steady progress in commercialization in China, having received CE marking and achieved commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]
心通医疗上半年净亏损收窄约83%，VitaFlow Liberty海外收入增长两倍以上